.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,955,426

« Back to Dashboard

Details for Patent: 5,955,426

Title: Cyclic hexapeptide somatostatin analogues
Abstract:This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radiosiotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.
Inventor(s): Dean; Richard T (Bedford, NH), McBride; William (Summit, NJ), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jun 30, 1997
Application Number:08/776,160
Claims:1. A composition comprising a pharmaceutically acceptable carrier or excipient and a somatostatin receptor-binding peptide having a formula:

wherein

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, Ain;

B.sup.2 is D-Trp, L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Ace, Apc, Aes, Aps;

B.sup.4 is Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva or Aib;

C.sup.4 is an L-.alpha.-amino acid having a sidechain covalently linked to a second peptide comprising from 11 to about 25 amino acid residues and having a carboxyl terminal carboxylic acid or a second peptide comprising from 11 to about 25 amino acid residues and having a carboxyl terminal amide; and

A.sup.4 is a lipophilic D-amino acid, a lipophilic L-(.alpha.-N-alkyl) amino acid, L-proline;

wherein the peptide is cyclized through a covalent linkage between an .alpha.-amino terminus of residue A.sup.4 and an .alpha.-carboxyl terminus of residue C.sup.4.

2. The composition of claim 1, wherein the sidechain of residue C.sup.4 is covalently linked through a bivalent linking group selected from the group consisting of:

a sulfur atom, an oxygen atom, an amine or substituted amine, and groups having the formula

wherein each R is independently H or lower alkyl, and two geminal R groups may be taken together as a lower alkylidene.

3. The composition of claim 2, wherein the sidechain of residue C.sup.4 is covalently linked through a thioether group to said second peptide.

4. The composition of claim 1, wherein B.sup.1 is phenylalanine or tyrosine, B.sup.2 is D-tryptophan, B.sup.3 is lysine and B.sup.4 is threonine or valine.

5. A composition comprising a pharmaceutically acceptable carrier or excipient and a somatostatin receptor-binding peptide having a formula:

wherein

B.sup.1 is D-Phe, L-Phe, D-Tyr, L-Tyr, D-Nal, L-Nal, Ain;

B.sup.2 is D-Trp, L-Trp;

B.sup.3 is D-Lys, L-Lys, Hly, Achxa, Amf, Aec, Apc, Aes, Aps;

B.sup.4 is Thr, Ser, Val, Phe, Ile, Abu, Nle, Leu, Nva, or Aib;

A.sup.4 is a lipophilic D-amino acid, a lipophilic L-(.alpha.-N-alkyl) amino acid, L-proline;

C.sup.4 is an L-.alpha.-amino acid having a sidechain of formula

where n is an integer from 1-4 an wherein R.sup.1 is --CH.sub.2 COR.sup.2, where R.sup.2 is selected from the group consisting of a second peptide comprising from 11 to about 25 amino acid residues and having a carboxyl terminal carboxylic acid and a second peptide comprising from 11 to about 25 amino acid residues and having a carboxyl terminal amide,

wherein the peptide is cyclized through a covalent linkage between an .alpha.-amino terminus of residue A.sup.4 and an .alpha.-carboxyl terminus of residue C.sup.4.

6. The composition of claim 5, wherein B.sup.1 is phenylalanine or tyrosine, B.sup.2 is D-tryptophan, B.sup.3 is lysine and B.sup.4 is threonine or valine.

7. The composition of claim 1-5 or 6, or 7, further comprising a radiosiotope of iodine.

8. The composition of claim 7, wherein the radioisotope is I-125 or I-131.

9. A method of performing radioisotope-guided surgery, a radiodiagnostic procedure, or a radiotherapeutic procedure comprising the step of administering an effective amount of the composition of claim 11.

10. The composition of claim 1 or 2, wherein the peptide is chemically synthesized in vitro.

11. The composition of claim 10, wherein the peptide is synthesized by solid phase peptide synthesis.

12. A method for alleviating a somatostatin-related disease in an animal comprising the step of administering a therapeutically effective amount of the composition of claim 1, 2, 3, 4, 6, or 7 to said animal.

13. The method of claim 12, wherein the animal is a human.

14. A composition of matter according to claim 1 wherein the sidechain of C.sup.4 is covalently linked to an amino acid, and amino acid amide, or a peptide comprised of 2 to 10 amino acids.

15. A composition comprising a pharmaceutically acceptable carrier or excipient and a peptide having a formula selected from the group consisting of:

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.K.amide);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CONH.sub.2);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 COOH);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)GC.amide);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)KCYRALVDTLKFVTQAEGAK.amide);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)GCRALVDTLKFVTQAEGAK.amide);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)KCKRALVDTLKFVTQAEGAK.amide);

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)GCYRALVDTLKFVTQAEGAK.amide); and

cyclo.(N--CH.sub.3)F.YW.sub.D KV.Hcy(CH.sub.2 CO.(.epsilon.-K)YRALVDTLKFVTQAEGAK.amide).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc